<DOC>
	<DOCNO>NCT02559206</DOCNO>
	<brief_summary>The objective study evaluate safety , efficacy , dose response two delayed release formulation linaclotide ( DR ; DR formulation 1 DR1 ; DR formulation 2 DR2 ) administer orally patient irritable bowel syndrome constipation ( IBS-C ) . Additional objective include understand two DR formulation compare FDA-approved 290 μg LINZESS® ( immediate release [ IR ] formulation linaclotide ) .</brief_summary>
	<brief_title>Trial Linaclotide Patients With Irritable Bowel Syndrome With Constipation ( IBS-C )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Patient complete colonoscopy accord AGA criterion , clinically significant finding Patient clinically significant finding physical examination clinical laboratory test Patient meet protocol criterion diagnosis IBSC Patient demonstrate continued IBSC Pretreatment Period Patient maintain minimum level compliance daily diary Patient history loose watery stool Patient symptom diagnose medical condition may contribute abdominal pain Patient structural abnormality gastrointestinal ( GI ) tract disease condition affect GI motility Patient protocolexcluded clinically significant medical surgical history could confound study assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>